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Summary: A new antiserum (Ab GiseDe) raised in sheep against extracted human parathyrin was evaluated and
compared with an established antiserum (Ab S<478 VI) under several test conditions.
The assay system contained an extracted 1—84 human parathyrin standard and a 1—84 bovine parathyrin tracer. The
total assay time was 24 h and the main assay characteristics as follows:
Bo/1 0,28 ± 0.02 and 50% intercept 553 ± 47 U - 1. The corresponding data for Ab S-478 VI were:
Bö/T 0.23 ± 0.02 and 50% intercept 890 ± 142 U - 1.
The normal range in 152 nprmocalcaemic volunteers (age range 16-67 years) was 10.6-423 U - 1 (where 1 vial
MRC reference preparation 75/549 for human parathyrin = 25 U), compared with 0-300 U - 1 for Ab S-478 VI.
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With the new antiserum, differentiation between hypoparathyroid patients and those with normal function was often
possible, and differentiation between normal and elevated levels, as in hyperparathyrinaemia, was very good.
Correlation between Ab Giselle and Ab S-478 VI in 80 normal volunteers was positive (r ^ 0.450, p = 0.01) although
the regression line showed that the antisera had different specificities (data for the regression line y - a + bx, a = 0.13,
b = 0.55).
Under the assay conditions, the association constant for Ab Giselle was 0.41 1014 1 · mol"1 in contrast to
Ab S478 VI which had a Ka of 0.53 X 10*° 1 · mof1 under identical conditions. Assays using Ab Giselle could be
performed at room temperature, whereas those using Ab S-478 VI performed best at 0 °C.
Preliminary results suggest that Ab Giselle is better for the routine assay of human parathyrin in serum than
Ab S478 VI, especially in the case of hypoparathyroid patients.
Erste Ergebnisse mit einem Antiserum gegen Parathyrin vom Menschen für einen homologen Radioimmuhassay
Zusammenfassung: Es wurde ein neues Sehafsantiserum (Ab Giselle) gegen extrahiertes Human-Parathyrin gewon-
nen, charakterisiert und mit einem etablierten Antiserum (Ab S-478 VI) verglichen. Im Radioimmunoassay wird ein
extrahierter 1-84 Human-Parathyrin-Standard und ein boviner Tracer eingesetzt. Die Gesamtdauer der Assays ist
24 Stunden mit folgenden Charakteristiken:
Bö/T = 0,28 ± 0,02, 50% Intercept 553 ± 47 U - 1. Die entsprechenden Daten für Ab S-478 VI sind:
Bö/10,23 ± 0,02, 50% Intercept 890 ± 142 U -1"1.
Der Normalbereich, gemessen in 152 normalcalcämischen Probanden im Alter zwischen 16 und 67 Jahren lag (2 s-Be-
reich) zwischen 10,6 und 423 U · 1 (standardisiert gegen MRC reference preparation 75/549, l Ampulle = 25 U
Human-Parathyrin).
Für Ab S478 VI lag der Normalbereich für die gleichen Probänden bei 0 bis 300 U · 1.
Mit dem neuen Antiserum war es häufig möglich, zwischen Patienten mit Nebenschilddrüsen-Unterfunktion und
Gesunden zu unterscheiden. Nur 9% der Patienten mit primärem Hyperparathyreoidismus hatten Parathyrinkon-
zentrationen im Normbereich.
Es bestand eine positive, wenn auch schwache Korrelation im Normalbereich zwischen den mit Ab-Giselle und
Ab S-478 VI gewonnenen Werten (r = 0,450, p = 0,01), die Regressionskurve zeigt jedoch, daß die beiden Antiseren
eine unterschiedliche Spezifität haben (Daten für die Regressionsgerade y = a + bx, a = 0,13,b = 0,55).
Unter Assay-Bedingungen liegt die Assoziationskonstante (Ka) für Ab-Giselle bei 0,41 -1014 l · mol"1, für
Ab S-478 VI bei 0,53 · 1010 l - mol"1. Das Temperaturoptimum für Ab-Giselle liegt bei etwa 7 °C, für Ab S-478 VI
bei 0 °C.
Unsere bisherigen Daten lassen Ab-Giselle für die Routinebestimmung von Human-Parathyrin im Serum geeigneter
erscheinen als Ab S-478 VI, besonders für die Unterscheidung zwischen gesunden und hyperparathyreoten Patienten.
Introduction
The measurement of human parathyrin has presented
problems in many laboratories, mainly because of the
low quality of antisera and tracer, not to mention
material for standards. During the past.few years, anti-
sera and standards have been prepared using extracted
human parathyrin, either from parathyroid adenomata
or from cell culture media. The assay described here
uses human standards, an antiserum raised against
human parathyrin and a bovine parathyrin tracer. The
results were compared with a system, which has been
used since 1977 for the analysis of over 5000 sera, and
in which the antiserum used was raised to a mixture of
bovine and porcine parathyrin (Ab S-478 VI). The
properties of S478 VI have been well documented
(1—4). The new antiserum (Ab Giselle) appears to have
better properties in differentiating between hypo-,
normo- and hyperparathyroid patients.
Materials and Methods
Antisera were raised in sheep by two of the authors (R. H. and
R. D. H.) against a mixture of bovine and porcine parathyrin
(Ab S-478 VI) and against extracted human parathyrin (Ab
Giselle).
Material for tracer was purchased from Inolex (Chicago, USA)
and was stated to be 1-84 bovine parathyrin. The lot No. used
for all· tracer preparations was 1515-COOl.
Material for standards was either extracted from human para-
thyroid adenomata purified and calibrated against MRC 75/549
human parathyrin 1-84 reference preparation, or extracted
from the media of preparations of human parathyroid adenoma
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cell cultures, purified and calibrated as above. This material
was coded "P 2" and is 1-84 human parathyrin (5).
Iodine for labelling was obtained from Amersham-Buchler
(Braunschweig, FRG). Donkey-anti-sheep serum was obtained
from Technia (London, GB) and was used at an initial dilution
of 1:12.
Tracer was prepared using the solid-phase lodogen method
already described (6) followed by a desalting step using Sephadex
SP-C 25 (6) and further purification over a 130 X 2.5 cm Ultrogel
AcA 54 column (2).
Standards were prepared in parathyrin-free serum (2) covering
the range 0-20.000 U · liter"1 human parathyrin. The assays
were coded and carried out as described in table 1.
Assay S-478 50P was carried out in 0.05 mol/1 Tris buffer pH 8.0
containing 2.5 g · liter"1 gelatin and assay G-50 DAB in the
same buffer, but with bovine serum albumin in place of the
gelatin.
Experiments to determine the antibody specificity were carried
out as described (1). Human parathyrin-fragments 1-34,
44—68 and 53—84 together with bovine parathyrin-fragments
28-48 were generously donated by Dr. M Rosenblatt, Boston,
USA. Human parathyrin-fragment 32-43 is the first pep tide
obtained from a programme undertaken to synthesise human
parathyrin by three of the authors (H. Z., M. C. and R. D. H.).
Results
Kinetic studies
The kinetics of tracer binding to Ab S-478 VI have
already been published (7) and those for Ab Giselle are
shown in figure 1. The kinetics cover a 6 h period for
three situations, namely B0, with serum D8 which lies
on the upper limit of the normal range, and for the
urispecific binding (UB). The studies have been carried
out at ambient temperature (21 °C), in a refrigerator
(7 °C) and in an ice-bath (0 °C). No preincubation was
performed. The results show that a preincubation is
preferable, as serum D8 and the B0 (zero standard in
parathyrin-free serum) run together in this study.
Optimal conditions for tracer binding are around
Tab. 1. Comparison of the assays using Ab S-478 VI and
Ab Giselle.
Ab 8^78 VI -
Assay code S-478 50P
50 μΐ serum or standard
100MlAbS=478VI
(initial dilution 1:2400)
18 h incubation 4 °C
(cold room)
50 μΐ tracer (ca. 170 Bq)
6 h incubation in an ice bath
50 μΐ carrier serum
1000 μΐ polyethylene gly col
(150 g - liter"1)
Vortex, centrifuge at 2000 £
for 10 min, aspirate off super-
natant, count for 2-3 min
in a T-counter
Ab Giselle -
Assay code G-50 DAB
50 μΐ serum or standard
100 μΐ Ab Giselle
(initial dilution 1:7500)
18 h incubation 4-10 °C
(normal refrigerator)
50 μΐ tracer (ca. 170 Bq)
6 h incubation 4-10 °C
50 μΐ sheep <y-globulin (7 μg)
100 μΐ Donkey-anti-sheep
serum (1:12 dilution)
1000 μΐ polyethylene glycol
(6O*g · liter"*)
Let stand at 4-10°C for
15 min, then follow same
procedure as for assay
S-478 50P
7000
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D 8 7 ' C
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Fig. 1. Kinetic studies using Ab Giselle. Studies at 3 tempera-
tures and 3 concentrations - zero standard (B0) control
serum on the upper limit of the normal range (D8) and
unspecific binding (UB). Tracer: bovine 1-84 parathyrin,
23 000 counts/mm.
6 h at 7 PC — this means that the assay can be run in a
normal refrigerator. The affinity constants for the anti-
sera under the conditions shown in table 1 were for Ab
Giselle 0.41 X 1014 1 - mol"1 and for Ab S-478 VI
0.53 Χ 1010 1 - mol"1.
Antibody specificity
The specificity of Ab S-478 VI has already been
published (1—3), and Ab Giselle is shown in figure 2.
When 1^84 bovine [12SI]parathyrin is used as tracer it
can be seen that Ab Giselle has the highest affinity
for the mid regional fragment 44—68 human parathyrin.
Affinity constants (K^) for intact human parathyrin
were found to be 0.56 X 101S 1 · mol"1 and for the
44-68 human parathyrin fragment 2 X 1015 1 · mol"1
using an 4-day assay as described (1). Ab S-478 VI, in
contrast, recognised these peptides with equal affinity
(Ka 0.6 Χ 10131 · mol"1) under identical assay condi-
tions. Ab Giselle, which resembles Ab S-469 (1) in its
specificity, does not react with 53—84 human para-
thyrin, 1—34 human parathyrin or 32—43 human para-
thyrin and only reacts poorly with 28—48 bovine para-
thyrin, showing that the Ab-determinants start around
amino-acids 44—48.
J. Clin. Chem. Clin. Biochem. / Vol. 18,1980 / No. 11
792 Wood et al.: Homologous radio immunoassay for human parathyrin
0.1 Q2 0.5 1 2 5 10 20 50 5001000
Parathyrin (-fragment) (jig/l)
Fig. 2. Specificity of Ab Giselle to different human parathyrin
and bovine parathyrin fragments as well as 1-84 human
parathyrin. 0—0 bovine, 28-48 Q—ο human, 1-34
ο—ο human, 53-84 Δ—Δ human, 75/549 *—± hu-
man, UP2" ·—e human, 44-68. All studies used
bovine [12SI]parathyrin (1-84) tracer and an assay time
of 4 days (1).
Tab. 2. Quality control parameters for assays G-50 DAB and
S478 50P.
1. Control sera
a) Assay G-50 DAB
K18
P2a
D8
P7P
KN2
Parathyrin
mean
(U · liter'1)
23.3
405
440
2197
4019
S.D.
(U - liter"1
14.1
65.8
59.8
345
808
C.V.
60.7
16.2
13.6
15.7
22.4
33.7
16.3
14.8
23.3
35.6
b; Assay S478 50P
K18 90.8 30.6
P2a 146 23.8
D8 450 66.6
P7P 3391 789
KN2 4995 1779
2. Curve parameters .
a) Assay G-50 DAB
B /T 0.288 ± 0.021 - C. V. 7.46%
50% intercept 553 ± 47 U · liter"1 - C. V. 8.51%
b) Assay S-478 50P
Bo/7 0.230 ± 0.018 - C.V. 7.71%
50% intercept 890 ± 142 U · liter"1 - C. V. 15.9%
Data from 18 assays for G-50 DAB and from 16 assays for
S-478 50P.
Quality control parameters in both assays
Table 2 shows the inter-assay coefficients of variation
(C. V.) of 5 control sera and the variation of the tracer
binding (expressed as B0/T) and the 50% intercept of
the standard curve. The results are from 18 G-50 DAB
and 16 S478 50P assays, the control sera are from
defined patient groups, namely: Κ 18 is an outdated
blood plasma sample, P2a a pooled serum from normal
levels in the S-478 SOP assay, D8 a pooled serum from
patients undergoing digoxin therapy, P7P a pooled
serum from patients with primary hyperparathyrinaemia,
and KN2 a serum from patients with secondary hyper-
parathyrinaemia. Typical standard curves are shown in
figure 3 in which the same tracer and standards were
usecL Both assays were carried out simultaneously. The
C. V. show the typical U-form of the concentration
dependence of the precision profile.
Normal range
Figure 4 shows the distribution of 152 normocalcaemic
volunteers measured in the G-50 DAB assay and of
118 normals in the S-478 50P assay.
The 95% confidence limits of the G-50 DAB assay were
10.6-423 U - liter"1 and 0-234 U - liter"1 for the
S-478 50P assay. Although the distribution of values
was slightly skewed in each case, it did not differ signifi-
cantly from a normal Gaussian curve.
Figure 5 shows the distribution of 88 sera measured at
the same time in both assay systems with S478 SOP on
the X-axis. The correlation was significant (r = 0.450,
ρ = 0.01) although it is plain to see that the two antisera
have different specificities, as shown by the intercept
of 130 U · liter"1 and slope of 0.55. The lines AC and BC
enclose the normal range of both assays and the lines
1.00
> 0.50
3
.2
1
S 478-50 Ρ
~ G 5 0 - D A
S478-50P
G 5 0 - D A B
28 250 2222 20000
Human 1-84 parothyrin standard [U/1]
Fig. 3. Typical standard curves for human 1 -^84 parathyrin
standard using Ab S478 VI (S 478-50 P) and Ab Giselle
(G 50-PAB). The dotted lines show the lower limit of
detection (zero - 3s value on the curve);
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100000 - 6 5 0 - D A B
Normal· Primary- Sec./tert. Normal- Primary- Sec^tert.
Collective hyper- Collective hyper-
parathyrinaemia parathyrinaemia
n=119 n = 80 n=66 n=152 n=80 n=66
Fig. 4. Scattergram showing normal volunteers, patients with
primary, secondary and tertiary hyperparathyrinaemia.
Values > 20000 U · liter"1 are shown as being equal to
the upper standard. S 478-50P = Antibody Ab S-478 VI
G 50-DAB = Antibody Giselle Limits of normal
range Level of highest standard.
„ 50 ' 150 250 350 450
.Human parathyrin (S47e-5QP)[U/U
Fig. 5. Correlation study on 88 normal sera measured in both
assays simultaneously. Regression data for the equation
y = a + bx: ayx = 130; byx = 0.55; for the equation
χ = a + by: axv - 57; bxy = 0.36. Correlation coefficient
r = 0.450. y
AXC and BXC enclose the space in which values are
pathological in both assays. The values enclosed by the
lines AjCB are normal in the S-478 50P assay, but
pathological in the G-50 DAB assay (n = 2); those
enclosed by the lines ACB! are nonruJ in the G-50 DAB
assay and pathological in the S-478 SOP assay (n = 5).
Regression data for axy and bxy are given (regression
line —) as well as for ayx and byx (regression line —).
Patients with hyperparathyrinaemia
Figure 3 shows the distribution of 80 patients with
surgically confirmed primary (extra-renal) hyperpara-
thyrinaemia as well as 66 patients with either secondary
(renal) hyperparathyrinaemia or tertiary (autonomous-
renal) hyperparathyrinaemia measured in both assay
systems. Using a non-parametric test (Wilcoxon-Rank-
Test) both assays were able to differentiate between
normo- and primary hyperparathyrinaemia, assay G-50
DAB with a significance ρ < 0.001 and S-478 50P with
a significance of ρ < 0.01.
Comparison of miscellaneous cases of interest
Table 3 shows ten cases where the clinician requested
serum parathyrin levels to aid him in his diagnosis. Three
cases are shown in patients undergoing total parathyroid-
ectomy with reimplantation of parathyroid tissue in the
right forearm (8). Case 5903 shows up to 21 day post
operative control of peripheral parathyrin levels. Case
5919 shows a non-functioning graft in a patient operated
on for tertiary hyperparathyrinaemia, and case 5668,
a functioning graft in a patient, also operated on for
tertiary hyperparathyrinaemia. Case 5801 shows a patient
with primary hyperparathyrinaemia who showed sup-
pression of parathyrin after a calcium infusion (9). The
values for levels of serum calcium, phosphorus and
creatinine are shown. From 10 patients who had under-
gone total parathyroidectomy without subsequent
reimplantation of glandular tissue, 9 had parathyrin
levels which were not significantly different from the
zero-standard.
Comparison of neck-vein catheters in two patients
with recurrent primary hyperparathyrinaemia
Two patients with recurrent primary hyperparathyrin-
aemia were catheterised to localise the parathyroid
adenoma. The sera were measured in both assay systems
and gave interesting results. In one patient, although
the numerical values were different, the ratio between
the values was more or less constant (G-50 DAB:
S478 50P - 2.38 ± 0.44:1, n = 12, range 1.77 - 3.13:1).
All 13 values were grossly elevated in both assays
(G-50 DAB 7400 - > 20000 U · liter"1 - S-478 50P
3300-> 20000 U-liter"1).
In a second patient, the results varied widely, being far
better in the G-50 DAB assay, where the adenoma was
easily localised. Here the ratio of the parathyrin levels
expressed as G-50 DAB: S-478 50P varied between 0.79:1
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Tab. 3. Miscellaneous cases of interest. Sera measured in both assay systems.
Case No.
5562
5596
5916
5850
5833
5929
5801
5919
5668
5903
Relevant details
Hypophosphataemia
Renal stones (Ca-oxalate)
Transient hypercalcaemia (Ca 2.4—2.8 mmol · 1)
Shock + hypocalcaemia
Persistent hypercalcaemia
Hypercalcaemia with changes in bone density
Primary hyperparathyrinaemia - before Ca infusion
- after Ca infusion
Parathyroid gland in lower right arm function test
Blood from right arm
Blood from left arm
(control made 3 day post-operatively)
As case 5919 above. Blood from right arm
Blood from left arm
(control made 7 day post-operatively)
Parathyroid gland transplant in lower right arm -
post operatively follow-up for function.
Blood from right arm
1 day postoperatively
2 days postoperatively
3 days postoperatively Ca-substitution
7 days postoperatively
10 days postoperatively
21 days postoperatively (Graft functioning,
Ca-substitution reduced)
Parathyrin
G-50 DAB
(U· liter'1 )
290
332
81
1490
300
460
5100
871
260
290
1170
472
40
62
60
70
44
269
S-478 50P
(Ü - liter1)
90
210
132
1650
161
100
4330
890
190
190
811
411
90
62
90
122
101
247
Serum^Ca
(mmol-r1)
2.22
2.41
2.55;
2.11
2.58
2.65
2.85
3.40
2.00
2.01
2.01
1.98
2.15
2.21
2.15
1.65
1.82
1.99
Serum-P
(mmol-f1)
0.56
0.83
1.38
1.65
0.87
1.24
0.81
0.99
2.10
2.09
2.17
2.23
1.24
1.57
1.63
1.59
1.82
2.44
Serum-
Creatinine
Oumol-f1)
80.0
97.0
62.5
264
88.3
51.1
52.8
56.9
1090
1100
493
501
259
255
263
255
277
284
and 7.03:1. The range of levels for G-50 DAB was
371-3520 U - liter"1 and for S-478 50P 133-671 U -
liter"1. The results from the second catheter emphasize
the differing specificity of the antisera.
Discussion
The determination of human parathyrin by radioimmunp-
assay has lost its "exclusiveness" now that sufficient
amounts of appropriate antisera cross-reacting with
human parathyrin (2,3) are available. Nevertheless most
assays are based on the use of heterologous materials.
There is still a need for human parathyrin as radioactive
tracer and for antisera raised against distinct human
parathyrin fragments, as parathyrin does not circulate
in blood as single hormone but as several pep tide frag-
ments. The physiological and clinical importance of
such fragments is beginning to be understood (10). In
this respect only assay systems using well characterized
antisera will be valid in interpreting deviations from the
physiological circulating peptide pattern.
The difference in specificity of the antisera described
here is shown by the results from control serum P2a
and the catheter studies. It appears that Ab S-478 VI
sees more of the intact 1-84 human parathyrin. This
corresponds to the characterization of the antiserum
by intact human parathyrin and its fragments (2,3).
The study of specificity for Ab Giselle reveals that it
sees more of the peptides in the 44-68 region of the
human parathyrin molecule. Neither antisera recognises
extreme N- or extreme C-regions of human parathyrin.
The wide experience using mid-regional specific antisera
has demonstrated that such antisera are extremely use-
ful for the detection of an overall overproduction of
parathyrin peptides associated with the common clinical
form of renal and extrarenal hyperparathyrinaemia. It
appears that there may be a species difference in the
type of antisera produced to human parathyrin. All
four antisera raised by two of the authors (R. H. and
R. D. H.) in sheep (S 478, S 469, Giselle, Claudine)
show ä specificity predominantly for the michregion
of the molecule. This is also true for the antibodies
raised in goats (personal communication Prof. R. Zieg·
ler, Heidelberg). In contrast, antibodies raised in guinea
pigs show more N- and/or C-terminal specificity. To
investigate these observations further, the metabolic
processes involved in degrading parathyrin must be
studied in different species. When this has been done,
perhaps the required specificity-'of an antiserum for
specific peptide sequences can be predicted, depending
upon which animal is used for raising the antisera. The
results of such a study could be of utmost importance
in the choice of cells to use in the production of mono-
clonal antisera.
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The advantage of the G-50 DAB assay using Ab Giselle
is that the standard curve is steeper and does not level
off at B/Bö of ca. 30%. In addition, the 50% intercept
lies considerably closer to the normal range than in the
case of Ab S-478 VI. The fact that the Ab Giselle is
raised against extracted human parathyrin is important
as it brings the establishment of a truely homologous
human parathyrin assay with human parathyrin tracer
one step closer. Ab Giselle is much less sensitive to
temperature than Ab S-478 VI, thus making the assay
conditions somewhat easier. In the assay S-478 SOP,
all reagents must be added at 0 °C, and the second
(tracer) incubation must be carried out in an ice bath.
Failure to do this results in a difference of binding
in the zero standard of up to 20% inside 10 min when
left to stand at room temperature after the tracer incuba-
tion. The difference in performance is reflected in the
affinity constants (KJ of both antibodies under assay
conditions. The Ka for S-478 VI is 0.53 - 10101 - mof1,
whereas that for Ab Giselle is 0.41 - 1014 1 · mof1 for
the assay run at 7 °C! Figure 1 shows indirectly that
Ab Giselle binds the tracer more rapidly than the human
parathyrin found in serum, thus making a preincubation
step necessary. The quality-control parameters show the
stability of the assay system using the new antiserum.
The fact that 9 from 10 hypoparathyroid patients had
levels below the normal range is encouraging, because
many antisera in current use are unable to differentiate
between normals and hypoparathyroid patients.
The clinical interpretation of the results from both
assays are mostly similar, but there are cases in which
different answers are given. These differences are not
yet fully understood. As the parathyrin result is usually
used to confirm a clinical diagnosis, then the differences
in the values given by both assays must be seen in con-
junction with other parameters such as serum calcium,
phosphorus, creatinine and alkaline phosphatase, although
they cannot yet be related to specific clinical symptoms.
Taking this into consideration the so-called normal para-
thyrin levels in the hands of clinicians specialising in
calcium metabolism disturbances take on a new meaning.
To conclude, this study has demonstrated that a new
antiserum to human parathyrin has proved to be useful
in the clinical diagnosis of calcium metabolism disorders
involving the parathyroid glands, as well as making the
laboratory determination of serum human parathyrin
easier and quicker to carry out. At the same time the
quality of the assay is improved by introducing a
double-antibody polymer enhanced separation of bound
and free antigen.
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